FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to heterologous chimeric proteins; it can be used in medicine for the cancer immunotherapy. Protein is constructed, including: (a) the first extracellular domain of transmembrane protein of type I on N-end, (b) the second extracellular domain of transmembrane protein of type II on C-end, and (c) a linker containing domain Fc hinge-CH2-CH3 originating from IgG1 or IgG4 and connecting the specified first and second extracellular domains. Transmembrane protein of type I and transmembrane protein of type II are, respectively: PD-1 and ligand OX40 (OX40L); PD-1 and ligand 4-1BB (4-1BBL); PD-1 and ligand GITR (GITRL); PD-1 and TL1A; TIM3 and OX40L; CD172a/SIRPα and OX40L; CD172a/SIRPα and ligand CD40 (CD40L); TIGIT and OX40L; BTLA and OX40L; TMIGD2 and OX40L; or CD115(CSF1R) and CD40L.
EFFECT: invention provides for the effective modulation of immune signals in the cancer immunotherapy.
42 cl, 17 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC PROTEINS BASED ON TIGIT AND LIGHT | 2018 |
|
RU2775490C2 |
| CSF1R-BASED CHIMERIC PROTEINS | 2018 |
|
RU2792239C2 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| ANTI-OX40 ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2753493C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
| BISPECIFIC BINDING PROTEINS AND APPLICATION WAYS THEREOF | 2017 |
|
RU2766199C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
